Pharmacogenomics in pediatric oncology: Australian adolescent or young adult and caregiver perspectives.

ABSTRACT:

Purpose

Preemptive pharmacogenomic (PGx) testing in pediatric oncology patients could reduce toxicity and improve efficacy of medications yet remains underutilized. Consumer identified implementation barriers have not been extensively explored nor included adolescent or young adult (AYA) patient perspectives. This study describes Australian pediatric oncology consumer perspectives on PGx testing, elucidating barriers to implementation.

Methods

A theory-informed, quantitative survey was used to assess knowledge and attitudes toward PGx in 38 AYA patients and 66 caregivers. Additionally, AYAs were assessed for autonomy using a validated scale.

Results

Participants viewed PGx testing positively, and 98% at least "somewhat agreed" that they would want to be tested/want th

SUBMITTER: Moore C 

PROVIDER: S-EPMC12552976 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature